Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib plus osimertinib dose-finding study in osimertinib-resistant EGFR-mutated non-small cell lung cancer
jRCTs051180008Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of afatinib and osimertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-limiting toxicity and Maximum tolerated/recommended dose. Started May 2018; status: completed.
02
Drugs
afatinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs051180008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180008.